Focused Alpha’s iShares iBonds Dec 2032 Term Corporate ETF IBDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$697K Buy
28,977
+998
+4% +$24.7K 0.17% 109
2026
Q2
$705K Buy
27,979
+326
+1% +$8.22K 0.18% 107
2026
Q1
$699K Buy
27,653
+455
+2% +$11.6K 0.22% 99
2025
Q4
$694K Buy
+27,198
New +$696K 0.2% 96

Other funds holding IBDX

Focused Alpha's IBDX Position: Q3 2026 in Review

Focused Alpha increased its iShares iBonds Dec 2032 Term Corporate ETF (IBDX) stake by 3.6% in Q3 2026, buying an estimated $24.7K and bringing the position to 28,977 shares worth $697K. The position accounts for 0.17% of the portfolio, ranked #109.

Focused Alpha first reported a position in IBDX in Q4 2025 and has held it in 4 quarters since. The position peaked at $705K in Q2 2026. 218 funds tracked by Wall St. Rank hold IBDX as of Q3 2026.

  • Focused Alpha held 28,977 shares of iShares iBonds Dec 2032 Term Corporate ETF worth $697K as of Q3 2026.
  • Focused Alpha bought 998 iShares iBonds Dec 2032 Term Corporate ETF shares in Q3 2026, an estimated $24.7K.
  • iShares iBonds Dec 2032 Term Corporate ETF made up 0.17% of Focused Alpha's portfolio in Q3 2026, its #109 holding.
  • Focused Alpha first reported a position in iShares iBonds Dec 2032 Term Corporate ETF in Q4 2025 and has held it in 4 quarters since.
  • Focused Alpha's iShares iBonds Dec 2032 Term Corporate ETF position peaked at $705K in Q2 2026.
  • 218 funds tracked by Wall St. Rank held iShares iBonds Dec 2032 Term Corporate ETF as of Q3 2026.

Based on Focused Alpha's 13F filing for Q3 2026, filed 20 Oct 2026.